BioMarin faces potential 3-month delay for Hemophilia A gene therapyR&D, TherapeuticsA request for additional data may cause a 3-month delay for potential approval of BioMarin Pharmaceutical’s hemophilia A gene therapy. Read more November 8, 2022/by BioSpace https://www.pharmalive.com/wp-content/uploads/2022/02/BioMarin-PKU-Study-Still-On-Hold-After-FDA-Requests-More-Data-BioSpace-2-18-22.jpeg 350 625 BioSpace https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png BioSpace2022-11-08 10:50:182022-11-08 10:50:18BioMarin faces potential 3-month delay for Hemophilia A gene therapy